Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Bercu, Joel P.
81  Ergebnisse:
Personensuche X
?
1

A Case to Support the Continued Use of Rifampin in Clinical..:

Bercu, Joel P. ; Ponting, David J. ; Ripp, Sharon L....
Clinical Pharmacology & Therapeutics.  116 (2024)  1 - p. 34-37 , 2024
Link: https://doi.org/10.1002/..
 
?
2

Comparison of the transgenic rodent mutation assay, error c..:

Bercu, Joel P. ; Zhang, Shaofei ; Sobol, Zhanna...
Mutation Research/Genetic Toxicology and Environmental Mutagenesis.  891 (2023)  - p. 503685 , 2023
Link: https://doi.org/10.1016/..
 
?
3

Acceptable intakes (AIs) for 11 small molecule N-nitrosamin..:

Bercu, Joel P. ; Masuda-Herrera, Melisa ; Trejo-Martin, Alejandra...
Regulatory Toxicology and Pharmacology.  142 (2023)  - p. 105415 , 2023
Link: https://doi.org/10.1016/..
 
?
4

Use of the bacterial reverse mutation assay to predict carc..:

Trejo-Martin, Alejandra ; Bercu, Joel P. ; Thresher, Andrew...
Regulatory Toxicology and Pharmacology.  135 (2022)  - p. 105247 , 2022
Link: https://doi.org/10.1016/..
 
?
5

Deriving Compound-Specific Exposure Limits for Chemicals Us..:

Drewe, William C. ; Dobo, Krista L. ; Sobol, Zhanna...
International Journal of Toxicology.  40 (2021)  3 - p. 285-298 , 2021
Link: https://doi.org/10.1177/..
 
?
6

Harmonized 3Rs-based non-mutagenic impurity qualification s..:

Mitra, Mayur S. ; Datta, Kaushik ; Hutchinson, Richard...
Regulatory Toxicology and Pharmacology.  122 (2021)  - p. 104895 , 2021
Link: https://doi.org/10.1016/..
 
?
7

Use of less-than-lifetime (LTL) durational limits for nitro..:

Bercu, Joel P. ; Masuda-Herrera, Melisa ; Johnson, George...
Regulatory Toxicology and Pharmacology.  123 (2021)  - p. 104926 , 2021
Link: https://doi.org/10.1016/..
 
?
8

Qualification of impurities based on metabolite data:

Weidolf, Lars ; Andersson, Thomas ; Bercu, Joel P....
Regulatory Toxicology and Pharmacology.  110 (2020)  - p. 104524 , 2020
Link: https://doi.org/10.1016/..
 
?
9

In Vivo Mutagenicity Testing of Arylboronic Acids and Ester:

Masuda‐Herrera, Melisa J. ; Dobo, Krista L. ; Kenyon, Michelle O....
Environmental and Molecular Mutagenesis.  60 (2019)  9 - p. 766-777 , 2019
Link: https://doi.org/10.1002/..
 
?
10

Using default methodologies to derive an acceptable daily e..:

Faria, Ellen C. ; Bercu, Joel P. ; Dolan, David G....
Regulatory Toxicology and Pharmacology.  79 (2016)  - p. S28-S38 , 2016
Link: https://doi.org/10.1016/..
 
?
11

Point of departure (PoD) selection for the derivation of ac..:

Bercu, Joel P. ; Morinello, Eric J. ; Sehner, Claudia..
Regulatory Toxicology and Pharmacology.  79 (2016)  - p. S48-S56 , 2016
Link: https://doi.org/10.1016/..
 
?
12

A harmonization effort for acceptable daily exposure applic..:

Hayes, Eileen P. ; Jolly, Robert A. ; Faria, Ellen C....
Regulatory Toxicology and Pharmacology.  79 (2016)  - p. S39-S47 , 2016
Link: https://doi.org/10.1016/..
 
?
13

Threshold of toxicological concern (TTC) for developmental ..:

Stanard, Brad ; Dolan, David G. ; Hanneman, William..
Regulatory Toxicology and Pharmacology.  72 (2015)  3 - p. 602-609 , 2015
Link: https://doi.org/10.1016/..
 
?
14

Application of the threshold of toxicological concern conce..:

Bercu, Joel P. ; Dolan, David G.
Regulatory Toxicology and Pharmacology.  65 (2013)  1 - p. 162-167 , 2013
Link: https://doi.org/10.1016/..
 
?
15

Advancing toxicology in RiskMAPP: Setting ADEs based on the..:

Bercu, Joel P. ; Sharnez, Rizwan ; Dolan, David G.
Regulatory Toxicology and Pharmacology.  65 (2013)  1 - p. 157-161 , 2013
Link: https://doi.org/10.1016/..
 
1-15